Myomo Secures $17.5 Million Loan for Growth

Myomo ( (MYO) ) has shared an announcement.

On November 4, 2025, Myomo, Inc. entered into a Loan and Security Agreement with Avenue Capital Management II, L.P. and Avenue Venture Opportunities Fund II, L.P., securing up to $17.5 million in term loans. This financial arrangement aims to support Myomo’s operational needs, including repaying existing borrowings and general corporate purposes. The company reported a strong third quarter in 2025, with revenues reaching $10.1 million, a 10% increase from the previous year, driven by record levels in both U.S. and international O&P revenues. Despite a decrease in gross margin due to higher costs, Myomo is focusing on cost reduction projects and strategic marketing initiatives like MyoConnect to enhance its patient pipeline and reduce costs.

The most recent analyst rating on (MYO) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Myomo stock, see the MYO Stock Forecast page.

Spark’s Take on MYO Stock

According to Spark, TipRanks’ AI Analyst, MYO is a Neutral.

Myomo’s overall stock score is primarily impacted by its financial performance challenges, including negative profitability and cash flow issues. Technical analysis indicates bearish momentum, further weighing on the score. While the earnings call showed some positive revenue growth, the operational challenges and increased costs limit the overall score.

To see Spark’s full report on MYO stock, click here.

More about Myomo

Myomo, Inc. is a wearable medical robotics company that specializes in providing increased functionality for individuals suffering from neurological disorders and upper-limb paralysis. The company focuses on the orthotics and prosthetics (O&P) market, both in the United States and internationally.

Average Trading Volume: 1,944,917

Technical Sentiment Signal: Sell

Current Market Cap: $32.27M

For detailed information about MYO stock, go to TipRanks’ Stock Analysis page.